Abstract CT237: A randomized phase 2 non-inferiority trial of (Z)-endoxifen + goserelin and exemestane + goserelin as neoadjuvant treatment for premenopausal women with ER+/HER2- breast cancer (EVANGELINE)Matthew P. Goetz, Steven C. Quay, Clàudia López et al.|Cancer Research|2025Cited by 0